证券代码：002734 证券简称：利民股份 编号：2019-03-06 | --- | --- | --- | |------------------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

股票代码：002734 股票简称：利民股份 利民控股集团股份有限公司投资者关系活动记录表 编号：2021-11-24 | --- | --- | |------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview and Recent Developments - Limin Holdings Group Co., Ltd. has successfully completed significant asset restructuring by acquiring the Weiyuan asset group, achieving performance commitments for two consecutive years in 2019 and 2020 [1] - Current ongoing projects include: - 12,000 tons/year of aluminum phosphonate project - 5,000 tons/year of glyphosate project - 500 tons/year of multiple pesticides including difenoconazole and tebuconazole, all progressing as planned [1] Group 2: Production Capacity and Market Demand - Glyphosate currently has a production capacity of 1,500 tons, with demand exceeding supply; an additional 5,000 tons capacity is expected to be operational next year [1] - The expansion of the 12,000 tons/year aluminum phosphonate capacity is driven by multinational company requirements, indicating strong market demand [1] Group 3: Market Trends and Pricing - The price of glyphosate has increased significantly due to supply shortages and rising raw material costs; however, prices are expected to stabilize as supply increases and energy restrictions are lifted [1] - The average selling price of the new biopesticide, difenoconazole, is currently between 2-3 million per ton, indicating a high profit margin [2] Group 4: Future Production and Technological Advancements - The company is enhancing its fermentation capacity, which is expected to nearly double from 550 tons, significantly increasing profit potential [2] - New fermentation facilities will allow for the production of various products, including abamectin and difenoconazole, leveraging the company's established technological advantages in the biopesticide sector [2]

股票代码：002734 股票简称：利民股份 编号：2022-02-23 利民控股集团股份有限公司投资者关系活动记录表 | --- | --- | |-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

股票代码：002734 股票简称：利民股份 利民控股集团股份有限公司投资者关系活动记录表 编号：2022-02-22 | --- | --- | |-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

编号：2022-01-12 股票代码：002734 股票简称：利民股份 利民控股集团股份有限公司投资者关系活动记录表 | --- | --- | |---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-11-17 股票代码：002734 股票简称：利民股份 利民控股集团股份有限公司投资者关系活动记录表 | --- | --- | |----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2022 was ¥1,233,401,008.19, representing a 6.25% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2022 was ¥27,682,864.86, a 22.00% increase compared to the same period last year[5] - The basic earnings per share for Q3 2022 was ¥0.07, reflecting a 16.67% increase year-over-year[5] - In Q3 2022, the company achieved operating revenue of CNY 1.233 billion, a year-on-year increase of 6.25%[13] - The net profit attributable to shareholders in Q3 2022 was CNY 27.68 million, representing a 22% increase year-on-year[14] - However, for the first nine months, the net profit attributable to shareholders decreased by 33.69% to CNY 179 million, primarily due to logistics disruptions and rising raw material costs[14] - Total operating revenue for the third quarter of 2022 reached CNY 4,042,093,577.37, an increase of 9.2% compared to CNY 3,701,281,699.85 in the same period last year[20] - Net profit for the third quarter was CNY 184,918,304.21, a decrease of 36.8% from CNY 292,207,347.02 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period reached ¥7,876,262,688.84, marking a 14.43% increase from the end of the previous year[5] - The company's total assets increased to CNY 7,876,262,688.84, compared to CNY 6,883,292,562.29 at the end of the previous year, reflecting a growth of 14.4%[19] - Current liabilities rose to CNY 3,694,169,280.94, an increase of 29.9% from CNY 2,846,889,618.25 year-on-year[19] - Long-term borrowings increased to CNY 429,960,000.00, compared to CNY 225,000,000.00 in the previous year, marking a growth of 91.1%[19] - The total liabilities of the company reached CNY 5,087,843,910.87, an increase of 27.1% from CNY 4,004,332,993.18 in the previous year[19] - The equity attributable to shareholders of the parent company was CNY 2,742,273,435.39, up from CNY 2,701,468,431.73 year-on-year, reflecting a growth of 1.5%[19] Cash Flow - The cash flow from operating activities showed a significant increase of 255.72%, totaling ¥381,653,409.53[5] - The net cash flow from operating activities for the first nine months was CNY 382 million, an increase of CNY 627 million year-on-year[14] - Net cash flow from operating activities was CNY 381,653,409.53, compared to a negative cash flow of CNY -245,085,620.65 in the previous period[25] - Cash inflow from operating activities totaled CNY 3,182,234,629.72, up from CNY 2,528,757,883.50 in the previous period[25] - Cash outflow from investing activities was CNY 1,566,044,922.18, compared to CNY 942,047,039.40 in the previous period[25] - Net cash flow from financing activities was CNY 561,099,301.25, down from CNY 995,865,505.58 in the previous period[25] - The ending balance of cash and cash equivalents was CNY 597,984,823.15, down from CNY 767,349,882.32 in the previous period[25] - The company received CNY 432,650,000.00 from investment recoveries, significantly higher than CNY 168,000,000.00 in the previous period[25] - The company paid CNY 465,034,117.44 in employee compensation, an increase from CNY 425,801,470.52 in the previous period[25] - The company reported a total cash inflow from financing activities of CNY 1,789,787,386.30, compared to CNY 1,898,330,000.00 in the previous period[25] Investments and Projects - The company's investment income decreased by 62.30% due to a decline in profits from associated companies[9] - The accounts receivable increased by 140.78%, primarily due to delayed payments[9] - The company reported a 36.79% increase in notes payable, attributed to an increase in bank acceptance bills[9] - The company organized 2,264 promotional activities and efficacy trials to enhance brand cultivation and promotion of core products[14] - The construction of the 5,000-ton glyphosate project was completed by September 30, 2022[15] - The company is advancing the new energy lithium salt project and the L-glyphosate project, with industrialization processes being accelerated[15] - The company plans to leverage rising prices of main products and decreasing raw material costs to enhance overall profitability in Q4 2022[15] - The company is focusing on international market expansion and product registration to drive sales growth[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,849[11] - The largest shareholder, Li Ming, holds 19.79% of the shares, with 28,580,000 shares pledged[11] Research and Development - Research and development expenses for the quarter were CNY 128,312,896.58, slightly down from CNY 133,976,717.04 in the same period last year[21] Financial Expenses - The company reported a decrease in financial expenses to CNY 11,697,349.91 from CNY 49,787,006.73 year-on-year[21] Comprehensive Income - The total comprehensive income for the period was CNY 187,268,818.12, a decrease from CNY 292,041,897.05 in the previous period[22] - Basic earnings per share decreased to CNY 0.48 from CNY 0.72 year-over-year[22]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥2,808,692,569.18, representing a 10.56% increase compared to ¥2,540,464,320.04 in the same period last year[22]. - The net profit attributable to shareholders decreased by 38.80% to ¥151,327,409.03 from ¥247,259,941.59 year-on-year[22]. - Basic earnings per share fell by 37.88% to ¥0.41, down from ¥0.66 in the same period last year[22]. - The company reported a decrease of 40.26% in net profit after deducting non-recurring gains and losses, amounting to ¥143,201,850.06 compared to ¥239,722,888.27 last year[22]. - The weighted average return on net assets decreased to 5.08% from 9.91% in the previous year, reflecting a decline of 4.83%[22]. - The company's net profit after deducting non-recurring gains and losses for the first half of 2022 was 15,108.3 million yuan, a decrease of 42.09% compared to the same period last year[181]. - The net profit for the first half of 2022 was CNY 159,208,488.86, a decrease of 40.7% from CNY 268,434,861.18 in the first half of 2021[194]. - The total comprehensive income for the first half of 2022 was CNY 160,135,316.13, compared to CNY 268,164,297.59 in the same period of 2021[195]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching ¥252,291,219.60, compared to a negative cash flow of ¥282,707,788.97 in the previous year, marking a 189.24% increase[22]. - Cash and cash equivalents at the end of the reporting period amounted to 1,272,853,600, representing 16.54% of total assets, an increase of 2.45% compared to the previous year[54]. - The company's cash interest coverage ratio improved to 6.55, a significant increase of 179.88% compared to -8.2 in the previous year[181]. - Operating cash flow for the first half of 2022 was CNY 252,291,219.60, compared to a negative cash flow of CNY -282,707,788.97 in the first half of 2021[200]. Assets and Liabilities - Total assets increased by 11.83% to ¥7,697,795,509.02 from ¥6,883,292,562.29 at the end of the previous year[22]. - The company's total liabilities increased to CNY 1,530,770,268.11, compared to CNY 1,202,865,554.25 in the previous year, reflecting a growth of 27.3%[194]. - The company's asset-liability ratio increased to 64.15% as of June 30, 2022, up from 58.17% at the end of 2021, representing a 5.98% increase[179]. - Total liabilities amounted to CNY 4.94 billion, up from CNY 4.00 billion, which is an increase of about 23.5%[188]. Investments and R&D - The company's R&D investment decreased by 8.16% to ¥82,025,940.12 from ¥89,309,896.54 year-on-year[47]. - The company has established five R&D platforms and is actively exploring new technology applications in "new energy materials" and "synthetic biology," including a joint venture for lithium battery chemical research and production[40]. - The company is focusing on technological upgrades and new product development to maintain competitive advantages and create new profit points[75]. Market Presence and Strategy - The company is recognized as a leading domestic pesticide manufacturer, with significant production capacity in key products such as mancozeb and flumioxazin[34]. - The company’s products have received various international certifications, including FDA and GMP, enhancing its competitive edge[35]. - The company’s sales market covers over 130 countries and regions, indicating a strong international presence[34]. - The company is focusing on green and safe agricultural practices, aligning with national policies for sustainable development in the pesticide industry[32]. Environmental Compliance - The company is committed to improving its environmental governance and carbon reduction capabilities in response to increasing ESG standards[75]. - The company has implemented continuous monitoring systems to ensure ongoing compliance with environmental standards[86]. - The company has established 3 comprehensive wastewater treatment facilities with a daily processing capacity of 8,300 tons, ensuring wastewater meets discharge standards before entering the local sewage treatment plant[89]. Safety and Risk Management - The company has a dedicated safety management team with 27 safety management personnel and 19 registered safety engineers to oversee production safety[105]. - The company emphasizes environmental protection and adheres to national standards, achieving no major safety accidents in the first half of 2022[104]. - The company has established a comprehensive emergency response plan, conducting 1 company-level emergency drill and 12 on-site drills in the first half of 2022[111]. Shareholder and Governance - The largest shareholder, Li Ming, holds 19.79% of the shares, totaling 73,734,050, with 28,580,000 shares pledged[160]. - The company has implemented stock incentive plans for executives, with various amounts of shares being released from restrictions[157]. - The company reported a total of 20,729 ordinary shareholders at the end of the reporting period[159]. Legal and Regulatory Compliance - There were no significant legal disputes or regulatory penalties reported during the reporting period[123]. - The company has adhered to the commitments made regarding compliance and operational responsibilities during the asset restructuring process[115].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,245,961,666.88, a decrease of 2.54% compared to CNY 1,278,419,638.94 in the same period last year[3] - Net profit attributable to shareholders was CNY 97,182,585.69, down 39.58% from CNY 160,851,094.64 year-on-year[3] - Total operating revenue for Q1 2022 was approximately CNY 1.25 billion, a decrease of 2.5% compared to CNY 1.28 billion in Q1 2021[15] - Net profit for Q1 2022 was approximately CNY 106.78 million, down 38.5% from CNY 173.63 million in Q1 2021[16] - Basic earnings per share decreased to CNY 0.26 from CNY 0.43 in the same period last year[17] - Tax expenses for Q1 2022 were approximately CNY 17.10 million, down from CNY 30.81 million in the previous year[16] - Other comprehensive income after tax showed a loss of approximately CNY 445.87 thousand, compared to a gain of CNY 168.93 thousand in Q1 2021[16] Cash Flow - The net cash flow from operating activities improved by 69.20%, reaching CNY -113,465,415.24 compared to CNY -368,442,247.53 in the previous year[3] - Cash flow from operating activities showed a net outflow of approximately CNY 113.47 million, an improvement from a net outflow of CNY 368.44 million in Q1 2021[18] - Cash flow from investing activities resulted in a net outflow of approximately CNY 302.34 million, compared to a net outflow of CNY 237.80 million in the previous year[20] - Cash flow from financing activities generated a net inflow of approximately CNY 288.80 million, down from CNY 931.64 million in Q1 2021[20] - The ending cash and cash equivalents balance was approximately CNY 567.04 million, a decrease from CNY 981.83 million at the end of Q1 2021[20] Assets and Liabilities - Total assets increased by 5.16% to CNY 7,238,255,556.57 from CNY 6,883,292,562.29 at the end of the previous year[3] - Current assets amounted to RMB 3,138,446,548.26, up from RMB 2,930,325,918.59, indicating an increase of about 7.1%[13] - The company's cash and cash equivalents decreased to RMB 930,641,977.76 from RMB 970,169,588.73, a decline of approximately 4.0%[12] - Accounts receivable rose significantly to RMB 496,270,352.64 from RMB 262,000,229.71, representing an increase of around 89.5%[12] - Inventory levels decreased to RMB 1,025,609,205.59 from RMB 1,065,709,257.32, a reduction of about 3.8%[13] - Total liabilities increased to RMB 4,251,100,897.43 from RMB 4,004,332,993.18, marking a rise of approximately 6.2%[14] - The company's equity attributable to shareholders reached RMB 2,799,825,271.18, up from RMB 2,701,468,431.73, reflecting an increase of about 3.6%[14] - Short-term borrowings rose to RMB 1,187,297,672.84 from RMB 1,063,637,697.40, an increase of approximately 11.7%[14] - The total non-current assets amounted to RMB 4,099,809,008.31, an increase from RMB 3,952,966,643.70, indicating a growth of approximately 3.7%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,932[9] - The top shareholder, Li Ming, holds 19.79% of the shares, amounting to 73,734,050 shares, with 28,580,000 shares pledged[9] Financial Expenses and Income - The company reported a 101.35% increase in financial expenses, primarily due to increased interest from convertible bond issuance[7] - The company's investment income decreased by 60.76%, attributed to market supply and demand changes affecting the profitability of its associate company[7] Government Subsidies - The company received government subsidies amounting to CNY 3,558,204.49 during the reporting period[5] Audit Status - The first quarter report has not been audited[21]